This content is first seen at HSA
Disclaimer: The information provided in this site is correct at the time of publication. POMConnect assumes no responsibility or liability for any errors or omissions in the content of this site.
| Product Name | KEYTRUDA SOLUTION FOR INFUSION 25MG/ML |
| Active Ingredient | Pembrolizumab |
| Product Registrant | MSD PHARMA (SINGAPORE) PTE. LTD. |
| Date of Approval | 14/07/2023 |
| Indications: KEYTRUDA, as monotherapy, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adults patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC (Non-small cell lung cancer). | |
| Product Name | OPDIVO 10 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION. |
| Active Ingredient | Nivolumab. |
| Product Registrant | BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD. |
| Date of Approval | 19/07/2023 |
| Indications: OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥1%. OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥1%. | |
| Product Name | DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 300 MG/2 MLDUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 MG/1.14 ML |
| Active Ingredient | Dupilumab |
| Product Registrant | SANOFI-AVENTIS SINGAPORE PTE LTD |
| Date of Approval | 26/07/2023 |
| Indications: DUPIXENT is indicated for the treatment of adults and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis who require chronic treatment and whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. | |
Link to the original news (HSA) :
